Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has had its market filing for Scemblix (asciminib) accepted for review by China’s National Medical Products Administration (NMPA). Scemblix is a Specifically Targeting the ABL Myristoyl Pocket (STAMP) inhibitor, which is filed for the treatment of chronic myeloid leukemia (CML). As the world’s only STAMP inhibitor, Scemblix is designed to tackle tyrosine kinase inhibitor (TKI) treatment resistance and intolerability in the later-line treatment of CML.
Asciminib functions as an allosteric inhibitor, distinguishing itself by not binding to ATP sites. Instead, it uniquely binds to the myristoyl pocket of BCR-ABL1. The drug has demonstrated nanomolar level activity against tumors harboring the T315I antibiotic mutation, even in cases with drug-resistant mutations in the myristoylation region and its surroundings.- Flcube.com
